Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial

详细信息    查看全文

• 作者：Matteo Lambertini ; Paolo Bruzzi ; Francesca Poggio…
• 关键词：Pegfilgrastim ; Timing ; Dose ; dense chemotherapy ; Breast cancer ; Safety
• 刊名：Supportive Care in Cancer
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：24
• 期：3
• 页码：1285-1294
• 全文大小：378 KB
• 参考文献：1.Bonilla L, Ben-Aharon I, Vidal L, et al (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102:1845–1854PubMedCentral CrossRef PubMed
  2.Aapro MS, Bohlius J, Cameron DA, et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32CrossRef PubMed
  3.Crawford J, Caserta C, Roila F, Guidelines Working Group ESMO (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(Suppl 5):v248–v251CrossRef PubMed
  4.Smith TJ, Khatcheressian J, Lyman GH, et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205CrossRef PubMed
  5.Yang B-B, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50:295–306CrossRef PubMed
  6.Holmes FA, O’Shaughnessy JA, Vukelja S, et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727–731CrossRef PubMed
  7.Green MD, Koelbl H, Baselga J, et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35CrossRef PubMed
  8.Siena S, Piccart MJ, Holmes FA, et al (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep 10:715–724PubMed
  9.Burstein HJ, Parker LM, Keshaviah A, et al (2005) Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 23:8340–8347CrossRef PubMed
  10.Arshad M, Seiter K, Bilaniuk J, et al (2005) Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol 23:8533–8534CrossRef PubMed
  11.Watring NJ, Wagner TW, Stark JJ (2007) Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. Am J Emerg Med 25:247–248CrossRef PubMed
  12.Hershman D, Neugut AI, Jacobson JS, et al (2007) Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99:196–205CrossRef PubMed
  13.Del Mastro L, De Placido S, Bruzzi P, et al (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2  ×  2 factorial, randomised phase 3 trial. Lancet 385:1863–1872CrossRef PubMed
  14.Giles FJ, Shen Y, Kantarjian HM, et al (2001) Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma 42:67–73CrossRef PubMed
  15.Ganzel C, Becker J, Mintz PD, et al (2012) Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 26:117–122CrossRef PubMed
  16.Senkus E, Kyriakides S, Penault-Llorca F et al (2013) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 Suppl 6:vi7–23.
  17.NCCN Clinical Practice Guidelines in Oncology. http://​www.​nccn.​org/​professionals/​physician_​gls/​f_​guidelines.​asp#breast . Accessed 20 July 2015.
  18.Rossi L, Tomao F, Lo Russo G, et al (2013) Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. Ther Clin Risk Manag 9:457–462PubMedCentral CrossRef PubMed
  19.Lambertini M, Del Mastro L, Bellodi A, Pronzato P (2014) The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 89:112–128CrossRef PubMed
  20.Engert A, Bredenfeld H, Döhner H, et al (2006) Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica 91:546–549PubMed
  21.Zwick C, Hartmann F, Zeynalova S, et al (2011) Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 22:1872–1877CrossRef PubMed
  22.Whitworth JM, Matthews KS, Shipman KA, et al (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112:601–604CrossRef PubMed
  23.Burris HA, Belani CP, Kaufman PA, et al (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 6:133–140PubMedCentral CrossRef PubMed
  24.Loibl S, Mueller V, von Minckwitz G, et al (2011) Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer 19:1789–1795CrossRef PubMed
  25.Skarlos DV, Timotheadou E, Galani E, et al (2009) Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Oncology 77:107–112CrossRef PubMed
  
• 作者单位：Matteo Lambertini (1)
  Paolo Bruzzi (2)
  Francesca Poggio (1)
  Simona Pastorino (1)
  Giovanni Gardin (1)
  Matteo Clavarezza (3)
  Claudia Bighin (1)
  Paolo Pronzato (1)
  Lucia Del Mastro (4)
  
  1. Department of Medical Oncology, U.O. Oncologia Medica 2, IRCCS AOU San Martino-IST, Largo Rosanna Benzi, 10, 16132, Genova, Italy
  2. Department of Epidemiology, IRCCS AOU San Martino-IST, Genova, Italy
  3. Department of Medical Oncology, U.O. Oncologia Medica, Ospedali Galliera, Genova, Italy
  4. Department of Medical Oncology, U.O. Sviluppo Terapie Innovative, IRCCS AOU San Martino-IST, Genova, Italy
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Nursing
  Nursing Management and Research
  Pain Medicine
  Rehabilitation Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-7339

文摘

Purpose To evaluate the safest timing of pegfilgrastim administration in dose-dense anthracycline- and taxane-based chemotherapy, three different cohorts of patients enrolled in the Gruppo Italiano Mammella (GIM) 2 study and treated at the coordinating center received pegfilgrastim 24 h (cohort A) or 72 h (cohort B) or 96 h (cohort C) after chemotherapy.